Some info for your reading pleasure Thank you, Tara Tara Johnson ________________________________ From: Prime and Magellan Rx <growthmarketingandtraining@primetherapeutics.com> Sent: Thursday, March 28, 2024 4:09:22 PM To: Tara Johnson <tjohnson@netroopers.org> Subject: All about GLP-1s 📈 The evolution of GLP-1s [The evolution of GLP-1s] What’s the hype? It's no surprise that glucagon like peptide-1 (GLP-1) drugs have taken the health care industry by storm. GLP-1s, originally designed to treat diabetes, are now being recognized for their potentially drastic weight loss transformations, sparking a seismic demand for these drugs and creating shortages for diabetic patients in need. In fact, in under two years, prescriptions for GLP-1s nearly doubled1. While the FDA has approved select GLP-1 therapies for weight loss, utilization trends show a dramatic increase in the use of unapproved type 2 diabetes GLP-1 therapies for weight loss. What’s on the horizon? [https://go.primetherapeutics.com/l/343791/2024-03-28/2b13wlw/343791/17116473...] When we look at historical utilization and spend patterns, we forecast that increasing GLP-1 weight loss utilization by just 1% of an insured population would drive a 5% increase in self-insured employer drug spend, totaling a rise of $10+ in costs per member per month (PMPM). Ready to dive deeper? The trends are clear: GLP-1s aren’t going anywhere. But we also still have much to learn about these relatively new therapies. Using the link below, take a look through our unique clinical lens with The evolution of GLP-1s, designed to deliver management strategies to help you develop a holistic approach to capitalize on the opportunities in this space. You’ll also learn more about our real-world analysis, see the pipeline for GLP-1s and gain access to valuable information spend and trend data. Discover our individualized strategy<https://go.primetherapeutics.com/e/343791/n---glp-1--fr-sMGUxZTY5MTk0MzE/2b13xfw/1640165219/h/jQqGrTMNeLnu8yQGtRiO1rzoPJWbF7xxC5FjGYPgcxw> 1 Internal Prime Therapeutics and Magellan Rx analysis, 2023 2 Internal 2023 Prime Therapeutics and Magellan Rx analytics based on current GLP-1 list prices, including, but not limited to, Wegovy® and Zepbound® [http://go.primetherapeutics.com/l/343791/2018-01-31/5hdlpc/343791/21694/5738...] <https://go.primetherapeutics.com/e/343791/company-prime-therapeutics-/2b13xfz/1640165219/h/jQqGrTMNeLnu8yQGtRiO1rzoPJWbF7xxC5FjGYPgcxw> [http://go.primetherapeutics.com/l/343791/2018-01-31/5hdlpf/343791/21696/5738...] <https://go.primetherapeutics.com/e/343791/Prime-PBM/2b13xg3/1640165219/h/jQqGrTMNeLnu8yQGtRiO1rzoPJWbF7xxC5FjGYPgcxw> [http://go.primetherapeutics.com/l/343791/2018-01-31/5hdlph/343791/21698/5738...] <https://go.primetherapeutics.com/e/343791/PrimeTherapeutics-/2b13xg6/1640165219/h/jQqGrTMNeLnu8yQGtRiO1rzoPJWbF7xxC5FjGYPgcxw> Is this email not displaying correctly? View it in your browser<https://go.primetherapeutics.com/webmail/343791/1640165219/1686b386c6a8c3fd92f6ae7b4d5efc29c8926bdd49e0f6fc26c918f5688da23b>. [blank] © 2023 Prime Therapeutics LLC <https://go.primetherapeutics.com/e/343791/en-html/2b13xg9/1640165219/h/jQqGrTMNeLnu8yQGtRiO1rzoPJWbF7xxC5FjGYPgcxw> |<https://go.primetherapeutics.com/e/343791/5jsGMkJs2BtKhuZIM3D-reserved-0/2b13xgd/1640165219/h/jQqGrTMNeLnu8yQGtRiO1rzoPJWbF7xxC5FjGYPgcxw> Magellan Rx Management, LLC, a Prime Therapeutics LLC company | PrimeTherapeutics.com<https://go.primetherapeutics.com/e/343791/en-html/2b13xg9/1640165219/h/jQqGrTMNeLnu8yQGtRiO1rzoPJWbF7xxC5FjGYPgcxw> | Update email preferences<https://go.primetherapeutics.com/health_plan_preference_page?ehash=1686b386c6a8c3fd92f6ae7b4d5efc29c8926bdd49e0f6fc26c918f5688da23b&email_id=1640165219&epc_hash=3AAzaGraNwxs4-t-SucgsSQ-2b7ejoAMIItzQEV4s2o> | Contact us<mailto:growthmarketingandtraining@primetherapeutics.com> [https://go.primetherapeutics.com/r/343791/1/1640165219/open/1]